Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norpsilocin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Subcutaneous, Oral, Sublingual, Buccal, Topical, Inhalation, Intravenous, Intramuscular, Transdermal, Intranasal
01
Overview
**Norpsilocin** is a tryptamine alkaloid (C11H14N2O, MW 190.24 g/mol) identified in 2017 in the hallucinogenic mushroom *Psilocybe cubensis*, where it occurs naturally and has been reported as a potential dephosphorylated metabolite of baeocystin. It acts as a near-full **agonist at the 5-HT2A receptor**, exhibiting higher potency than psilocin, with additional affinity for other serotonin receptors; it demonstrates good metabolic stability, blood-brain barrier penetration in animal models, and psychedelic properties associated with tryptamines.[1][5][7][8]
- Other names
- 4-hydroxy-N-methyltryptamine4-HO-NMT3-[2-(methylamino)ethyl]-1H-indol-4-ol
02
Targets
HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR7 (5-hydroxytryptamine receptor 7)HTR1B (5-Hydroxytryptamine Receptor 1B)SIGMAR1 (Sigma non-opioid intracellular receptor 1)TMEM97 (Sigma-2 receptor complex (TMEM97/PGRMC1))HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)
Beyond the preview
Go deeper on norpsilocin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norpsilocin.